China is advancing with two more COVID-19 vaccines in the regulatory process, one from the state-owned company Sinopharm and another from the private company CanSino.
Both vaccines were submitted to regulators for approval this week. CanSino said Chinese regulators are reviewing their application for the COVID-19 vaccine in a dossier released on Wednesday.
Sinopharm Branch, Wuhan Institute of Organic Products, announced on Wednesday that it had filed an application on Sunday and was being reviewed by regulators.
China has already approved two vaccines it has used in a mass immunization campaign. One of them is also from Sinopharm, but was developed by its Beijing branch. The other is the Sinovac vaccine.
Sinopharm’s power in Wuhan is 72.51% efficient, the company said. Both Sinopharm injections are based on inactivated viruses, a traditional technology.
The CanSino vaccine is a single-dose injection that relies on a harmless virus from the common cold, called adenovirus, to deliver the spike gene to the virus in the body. The technology is similar to the Astrazeneca and Johnson & Johnson vaccines, which are based on different adenoviruses.
The CanSino vaccine is 65.28% effective, the company said on Wednesday.
No company has yet published data from their studies in peer-reviewed scientific journals.